DUVELISIB
| Brand name | COPIKTRA |
|---|---|
| Active ingredient | DUVELISIB |
| Strength | 25MG |
| Dosage form | CAPSULE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | September 2018 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 12213983 | April 2035 | use U-2412 |
| 8193182 | September 2032 | substance |
| RE46621 | May 2032 | substance, product |
| 9840505 | January 2032 | use U-2413 |
| 11312718 | January 2032 | product |
| 9216982 | January 2029 | use U-2412 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.